Analysts consider the potential for P&G splitting up or selling OTC or beauty care assets following CEO David Taylor's recent comments on possible moves with activist investor Trian. Analysts weigh in on the potential for sale or swap of brands and whether the moves would help.
Speculation is growing that Procter & Gamble Co., now that activist investor Trian Fund Management has a stake, will break up, divest more brands or arrange asset swaps with competitors, notably in the OTC drug and beauty product sectors.
Analysts have buzzed about P&G's prospects since Trian, a firm known to invest in large consumer companies before pressuring them...
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.
